Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.

Zanjirband, Maryam; Curtin, Nicola; Edmondson, Richard J; Lunec, John

Zanjirband, Maryam; Curtin, Nicola; Edmondson, Richard J; Lunec, John.

Afiliação

Zanjirband M; Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne NE2 4HH, United Kingdom.
Curtin N; Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne NE2 4HH, United Kingdom.
Edmondson RJ; Faculty Institute for Cancer Sciences, University of Manchester, Manchester M13 9WL, United Kingdom.
Lunec J; Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne NE2 4HH, United Kingdom.

Oncotarget ; 15: 142, 2024 Feb 22.

Article em En | MEDLINE | ID: mdl-38386812

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article